The U.S. Food and Drug Administration approved pharmaceutical giant Eli Lilly’s Insulin Jab, Onswik. The FDA approval for Lilly’s Onswik has introduced a new once-weekly basal insulin option for adults with type 2 diabetes in the United States. The treatment is designed to provide steady basal insulin coverage for seven days and can be used alongside diet and exercise to control high blood sugar.
The FDA decision marks the fourth global regulatory approval for Onswik. Before the U.S. approval, regulators in Europe, Mexico, and Japan had also approved Onswik for adults with type 2 diabetes.
What Is Eli Lilly’s Insulin Jab Onswik?
Onswik is a long-acting, or basal insulin. Basal insulin provides background insulin coverage to help control blood glucose between meals and overnight.
Eli Lilly’s insulin Onswik drug is specifically approved for adults with type 2 diabetes. It is not approved for people with type 1 diabetes because of the increased risk of severe hypoglycemia, or dangerously low blood sugar.
What Are the Trial Results For Eli Lilly’s Insulin Jab Onswik?
The FDA approval for Lilly’s Onswik was supported by Lilly’s Phase 3 QWINT clinical development program. The program enrolled more than 3,400 adults with type 2 diabetes across four studies. The clinical program included participants who were new to insulin as well as adults already using basal insulin.
The trials compared once-weekly Onswik with commonly used daily basal insulins. Across the QWINT studies, Onswik met the primary goal of non-inferior A1C reduction.
A1C is a blood test that estimates a person’s average blood glucose level over roughly the previous two to three months. “Non-inferior” means the trial showed that Onswik was not meaningfully worse than the comparison insulin for the study’s specified outcome.
The overall safety profile of Eli Lilly’s Onswik was similar to the daily basal insulins studied.
Common side effects of Onswik insulin jab include hypoglycemia, injection-site reactions, allergic reactions, itching, rash, swelling of the hands and feet, and weight gain.
What Are The Dosage Requirements of FDA-Approved Insulin Jab Onswik?
A major feature of the Lilly diabetes treatment Onswik is its weekly dosing schedule.
A once-daily basal insulin requires about 365 injections over a year. Onswik is designed for 52 weekly injections, potentially reducing the annual injection count by more than 300. Lilly says the comparison concerns injection frequency and is not a comparison of safety or effectiveness.
The company says the weekly approach could also provide greater flexibility for people who face the burden of regular insulin injections. However, whether a patient should use Onswik depends on their individual treatment needs and should be determined with a healthcare professional.
Will Eli Lilly’s Onswik Drug US Approval Increase Competition?
Lilly expects Onswik to become available in the U.S. in the coming months through the Onswik KwikPen in two concentrations: 500 units/mL and 1,000 units/mL.
FDA approval for Lilly’s Onswik also places Lilly in competition with Novo Nordisk’s Awiqli, another once-weekly basal insulin for adults with type 2 diabetes. The FDA approved Awiqli in March 2026, making Onswik the second weekly basal insulin approved by the U.S. regulator.
As treatment plans become increasingly diverse, the two products give healthcare professionals another category of insulin delivery to consider.
